Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07304089 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

A Phase 2 study of Dystonia, sponsored by Vima Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT07304089 is a Phase 2 study of Dystonia that is actively recruiting participants, run by Vima Therapeutics. The registered enrollment target is 100 participants, below the 537-participant average among 28 other Dystonia trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07304089, a Phase 2 study of Dystonia, is actively recruiting participants, sponsored by Vima Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Conditions Studied

Dystonia

Interventions

  • DRUG VIM0423
  • DRUG VIM0423 Placebo

Study Locations (20)

Arizona

  • Vima Site #039 - Scottsdale
  • Vima Site #004 - Scottsdale
  • Vima Site #028 - Sun City

Florida

  • Vima Site #009 - Gainesville
  • Vima Site #008 - Miami
  • Vima Site #031 - Orlando

California

  • Vima Site #042 - Irvine
  • Vima Site #030 - Los Angeles

Maryland

  • Vima Site #043 - Baltimore
  • Vima Site #007 - Olney

Michigan

  • Vima Site #037 - East Lansing
  • Vima Site #002 - Farmington Hills

Alabama

  • Vima Site #033 - Birmingham

Colorado

  • Vima Site #019 - Denver

Georgia

  • Vima Site #005 - Atlanta

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-02-05
Est. Completion 2027-05
Phase Phase 2

Sponsor

Vima Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07304089

The ClinicalTrials.gov registry entry for NCT07304089 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 537-participant average among 28 other Dystonia trials with a reported enrollment target (81% lower). The listed sponsor is Vima Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dystonia appearing as the primary indexed condition, and to 2 interventions - of which VIM0423 is the first listed.

NCT07304089 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, California.

Frequently Asked Questions

What is clinical trial NCT07304089 about?

NCT07304089 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia". Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms c...

What is the current status of trial NCT07304089?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-02-05. Estimated completion is 2027-05.

What conditions does trial NCT07304089 study?

This clinical trial studies the following conditions: Dystonia.

What interventions are being tested in trial NCT07304089?

The interventions under investigation include: VIM0423 (DRUG), VIM0423 Placebo (DRUG).

Who is sponsoring clinical trial NCT07304089?

This trial is sponsored by Vima Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07304089 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dystonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dystonia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.